ArticleLiver cancer2023

Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.

Masatoshi Kudo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.